Adverum Biotechnologies Completes IND Amendment And Prepares To Initiate The Phase 2 LUNA Trial Of ADVM-022 In Wet AMD
- Cash runway extended into 2025 due to corporate restructuring to prioritize the clinical development of ADVM-022 and provide additional resources beyond anticipated one-year topline results of the Phase 2 LUNA trial
-
Global Coalition For Adaptive Research, Biohaven, And Vigeo Announce Commencement Of Biohaven’s Troriluzole And Vigeo’s VT1021 In GBM AGILE Trial
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial
Biohaven and Vigeo Now Enrolling in GBM AGILE, Registrational
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today
NYC Healthy Tweets ‘Monkeypox vaccine doses have arrived in NYC! We plan to make appointments available starting
https://twitter.com/nycHealthy/status/1544693903407955968
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer’s Drug Due In January, FDA Reviews Roche’s Lymphoma Candidate, Rare Pediatric Tag For Kazia’s Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
InflaRx’s Stock Gains Following FDA Fast Track Status To Skin Disease Drug
The US Food and Drug Administration (FDA) granted a Fast Track designation to InflaRx’s (NASDAQ: IFRX) lead candidate Vilobelimab for the treatment of ulcerative Pyoderma Gangrenosum (PG).
Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week
Vera Therapeutics Completes Patient Enrollment In Phase 2b ORIGIN Clinical Trial Of Atacicept For The Treatment of IgA Nephropathy
Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced completion of